Science to Practice: Molecular-targeted Drug Delivery in Combination with Radiofrequency Ablation of Liver Cancer: A Magic Bullet?
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29045226.
- Also identified by DOI 10.1148/radiol.2017171527 and PMC identifier 5673055.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In an effort to improve the technical success rates and clinical outcomes of radiofrequency (RF) ablation, Yan et al validated the use of a tumor-penetrating peptide and thermosensitive doxorubicin (DOX)-loaded nanoparticles in combination with RF ablation in a hepatocellular carcinoma mouse model. By achieving higher chemotherapeutic drug concentrations in target lesions, fewer toxic effects, and improved survival end points in an animal tumor model, the authors conclude that superior tumor treatment with RF ablation is possible when combined with molecular-targeted drug delivery systems.
Medical subject headings
- Antineoplastic Agents
- Catheter Ablation
- Drug Carriers
- Liver Neoplasms, Experimental
- Molecular Imaging